| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- manufacturers
- Opevesostat
-
- $30.00
-
2026-07-27
- CAS:2231294-96-3
- Purity: 99.67%
- Supply Ability: 10g
|
| | 4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- Basic information |
| | 4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- Chemical Properties |
| Boiling point | 611.2±65.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | pka | 6.28±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | 4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- Usage And Synthesis |
| Uses | Opevesostat (MK-5684; ODM-208) is an orally active and selective CYP11A1 inhibitor. Opevesostat has the potential for the research of metastatic castration-resistant prostate cancer (mCRPC)[1]. | | References | [1] Fizazi, K. et al. 1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results. Annals of Oncology, Volume 35, S968. |
| | 4H-Pyran-4-one, 2-[(1,3-dihydro-2H-isoindol-2-yl)methyl]-5-[[1-(methylsulfonyl)-4-piperidinyl]methoxy]- Preparation Products And Raw materials |
|